Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 2 |
Small molecule drug | 1 |
Mechanism CDK1 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD3ε inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IL-6RA antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Nov 2023 |
Sponsor / Collaborator |
Start Date15 Mar 2023 |
Sponsor / Collaborator |
Start Date01 May 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Milciclib maleate ( CDK1 x CDK2 x CDK4 x TRKA ) | Hepatocellular Carcinoma More | Phase 2 |
Foralumab ( CD3ε ) | Multiple Sclerosis More | Phase 2 |
TZLS-501 ( IL-6RA ) | Inflammation More | Preclinical |
Colostrinin(Ludwik Hirszfeld Institute Of Immunology & Experimental Therapy) | Alzheimer Disease More | Pending |
OH-14 ( CFLAR ) | Neoplasms More | Pending |